Avoiding the Immunopathology Pitfalls of a COVID-19 Vaccine
In this blog, we explore the potential challenges in stimulating safe vaccine responses and outline the role that diagnostics will play in guiding their development.
See our Coronavirus Product Pipeline
The Native Antigen Company is developing an extensive range of antigens and antibodies for the human coronaviruses, including SARS-CoV-2 (COVID-19).
SARS-CoV-2 S1 and S2 Antigens Now Available
The Native Antigen Company is now offering recombinant S1 and S2 glycoproteins for SARS-CoV-2 (COVID-19) in response to urgent demand.
About The Native Antigen Company
The Native Antigen Company specialises in the development and manufacture of native and recombinant viral and bacterial antigens, antibodies and immunoassays, as well as bespoke product development and custom manufacturing. The company has decades of experience in producing high-quality proteins with its proprietary mammalian cell expression system to ensure correct glycosylation and proper folding. The Native Antigen Company’s high-quality reagents are widely adopted by leading pharmaceutical, in vitro diagnostic assay manufacturers, and academic groups in cutting-edge vaccine research and serology, where correct folding and glycosylation are vital.